Bloomberg ID: CCSC130 <Equity> Morningstar ID: F00000V3XE
The Constantia Capital Small-Cap Biotech+ Strategy is a passively managed strategy that aims to match the returns of Biotechnology, Life Sciences and Medical Device stocks in the Russell 2000.
Biotech+ stocks have excellent growth potential, buoyed by new discoveries. These Small-cap publicly traded stocks are highly levered to the success of their drugs and devices undergoing clinical trials. Demand from large-cap pharmaceuticals to fill their pipelines increases potential returns by way of mergers and acquisitions.